Header links
Intranet
Donate now
image/svg+xml Map
Contact us

Angel Michael Ortiz Zúñiga

Angel Michael Ortiz Zúñiga

Institutions of which they are part

Predoctoral researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca
Angel Michael Ortiz Zúñiga

Angel Michael Ortiz Zúñiga

Angel Michael Ortiz Zúñiga

Institutions of which they are part

Predoctoral researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Microperimetry and serum biomarkers for identifying type 2 diabetic patients with cognitive impairment. A cross-sectional and prospective study.

IP: Olga Simó Servat
Collaborators: Ana Boixadera Espax, Marina Giralt Arnaiz, Cristina Udina Argilaga, Angel Michael Ortiz Zúñiga
Funding agency: Instituto de Salud Carlos III
Funding: 82280
Reference: PI20/01703
Duration: 01/01/2021 - 30/06/2025

Estabilidad cerebral pre-frontal, clave para la acción contra la discapacidad en el envejecimiento: el proyecto FRONT STAGE.

IP: Marco Inzitari
Collaborators: Angel Michael Ortiz Zúñiga
Funding agency: Instituto de Salud Carlos III
Funding: 123420
Reference: PI19/00734
Duration: 01/01/2020 - 30/06/2024

MOPEAD

IP: Rafael Simó Canonge
Collaborators: Angel Michael Ortiz Zúñiga, Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 47268
Reference: 2018/VHIR/ORTIZ
Duration: 01/07/2019 - 30/06/2022

Related news

Dra. Andreea Ciudin

A new guideline proposes a change in the pharmacological approach to obesity

The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.

Dra. Andreea Ciudin, Marta Comas i Juan José Cortés

A new oral drug for obesity shows positive results in an international study

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

Equip del grup de Diabetis i Metabolisme del VHIR

Fundaluce supports research into a new therapeutic strategy for retinitis pigmentosa

Dr. Maria Llorián-Salvador, from the Diabetes and Metabolism Research Group at VHIR, is leading this project to identify new therapies for this inherited disease that causes progressive vision loss.

See more

Related professionals

Laia Josa Culleré

Laia Josa Culleré

Postdoctoral researcher
Head and Neck Cancer: Biomedical Research Cancer Stem cells
Read more
Maria Garcia Carrasco

Maria Garcia Carrasco

Reconstructive Surgery of the Locomotor System
Read more
Ester Sanchez Gavilan

Ester Sanchez Gavilan

Research technician
Stroke research
Read more
Rebeca Murillo Torres

Rebeca Murillo Torres

Research technician
Head and Neck Cancer: Biomedical Research Cancer Stem cells
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.